Foghorn Therapeutics Inc. (FHTX): Revenue
$30.91M
Year ended 2025-12-31
$36.74M
Trailing 12 months to 2026-06-30
+17.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.91M | +36.8% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $22.60M | -33.8% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $34.16M | +77.6% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $19.23M | n/m | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $1.32M | +206.7% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $430.0K | n/a | 2022-08-09, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $30.91M | +36.8% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $30.91M | +209.1% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $32.03M | +17.4% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $34.51M | +37.0% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.47M | +195.7% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $35.58M | +370.2% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $35.70M | +7.8% |
| Celularity Inc (CELU) | 2025-12-31 | $26.55M | -51.0% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $36.31M | +4.1% |
Compare FHTX, VSTM, ZOMDF, BHST side by side · Screen every company in Pharmaceutical Preparations ↗